Royce & Associates’s LifeMD LFMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.63M Sell
636,124
-565,527
-47% -$2.5M 0.02% 574
2026
Q1
$4.34M Buy
1,201,651
+292,000
+32% +$1.01M 0.04% 485
2025
Q4
$3.1M Buy
909,651
+95,200
+12% +$462K 0.03% 539
2025
Q3
$5.53M Buy
814,451
+44,000
+6% +$363K 0.06% 447
2025
Q2
$10.5M Sell
770,451
-384,780
-33% -$3.63M 0.11% 275
2025
Q1
$6.28M Buy
1,155,231
+39,240
+4% +$223K 0.07% 399
2024
Q4
$5.52M Buy
1,115,991
+214,950
+24% +$1.13M 0.05% 458
2024
Q3
$4.72M Buy
901,041
+114,710
+15% +$661K 0.04% 487
2024
Q2
$5.39M Sell
786,331
-15,264
-2% -$140K 0.05% 461
2024
Q1
$8.24M Sell
801,595
-31,031
-4% -$229K 0.07% 380
2023
Q4
$6.9M Sell
832,626
-263,882
-24% -$1.9M 0.06% 421
2023
Q3
$6.85M Buy
1,096,508
+76,426
+7% +$331K 0.07% 399
2023
Q2
$4.44M Sell
1,020,082
-50,000
-5% -$111K 0.04% 520
2023
Q1
$1.82M Buy
1,070,082
+91,306
+9% +$161K 0.02% 671
2022
Q4
$1.9M Buy
978,776
+126,232
+15% +$283K 0.02% 656
2022
Q3
$1.68M Buy
852,544
+260,058
+44% +$620K 0.02% 653
2022
Q2
$1.21M Buy
+592,486
New +$1.47M 0.01% 728

Other funds holding LFMD

Royce & Associates's LFMD Position: Q2 2026 in Review

Royce & Associates reduced its LifeMD (LFMD) stake by 47% in Q2 2026, selling an estimated $2.5M and leaving 636,124 shares worth $2.63M. The position accounts for 0.02% of the portfolio, ranked #574.

Royce & Associates first reported a position in LFMD in Q2 2022 and has held it in 17 quarters since. The position peaked at $10.5M in Q2 2025. 116 funds tracked by Wall St. Rank hold LFMD as of Q2 2026.

  • Royce & Associates held 636,124 shares of LifeMD worth $2.63M as of Q2 2026.
  • Royce & Associates sold 565,527 LifeMD shares in Q2 2026, an estimated $2.5M.
  • LifeMD made up 0.02% of Royce & Associates's portfolio in Q2 2026, its #574 holding.
  • Royce & Associates first reported a position in LifeMD in Q2 2022 and has held it in 17 quarters since.
  • Royce & Associates's LifeMD position peaked at $10.5M in Q2 2025.
  • 116 funds tracked by Wall St. Rank held LifeMD as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.